*	OR T3 T4
R1	Has_value Arg1:T1 Arg2:T2	
R2	Subsumes Arg1:T7 Arg2:T8	
R3	multi Arg1:T5 Arg2:T6	
R4	Subsumes Arg1:T14 Arg2:T15	
R5	AND Arg1:T13 Arg2:T14	
*	OR T9 T10 T11 T12
R6	Has_qualifier Arg1:T9 Arg2:T7	
R7	Has_qualifier Arg1:T9 Arg2:T5	
R8	Has_value Arg1:T20 Arg2:T19	
R9	AND Arg1:T18 Arg2:T20	
R10	Has_qualifier Arg1:T18 Arg2:T21	
R11	Has_value Arg1:T22 Arg2:T24	
R12	Has_qualifier Arg1:T22 Arg2:T23	
R13	Has_value Arg1:T25 Arg2:T26	
R14	Has_value Arg1:T27 Arg2:T28	
T1	Person 0 3	Age
T2	Value 7 18	18 and over
T3	Person 20 24	male
T4	Person 28 34	female
T5	Qualifier 51 75	histologically confirmed
T6	Procedure 51 65	histologically
T7	Qualifier 76 84	advanced
T8	Qualifier 86 94	stage IV
T9	Condition 96 110	gastric cancer
T10	Condition 112 117	NSCLC
T11	Condition 119 132	breast cancer
T12	Condition 136 150	ovarian cancer
T13	Procedure 163 174	monotherapy
T14	Drug 178 206	oral vascular targeting drug
T15	Drug 208 216	apatinib
T16	Non-representable 218 279	due to intolerability or inappropriateness of other therapies
T18	Condition 294 312	measurable lesions
T19	Value 314 319	=10mm
T20	Procedure 323 337	spiral CT scan
T21	Qualifier 350 360	RECIST 1.1
T22	Measurement 363 378	Blood pressured
T23	Qualifier 379 389	controlled
T24	Value 393 404	150/100 mHg
T25	Measurement 440 447	ECOG PS
T26	Value 457 472	between 0 and 1
T27	Observation 477 492	life expectancy
T28	Value 496 513	at least 3 months
T29	Informed_consent 516 667	Subjects who volunteer to participate in this study and have signed the Informed Consent Form (ICF), with good compliance with treatment and follow-up.
